A multicenter retrospective study to assess efficacy and safety of Daclatasvir and Asunaprevir combination therapy in Korean patients infected with HCV G1b without NS5A resistance.
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
 - Indications Hepatitis C
 - Focus Adverse reactions; Therapeutic Use
 
Most Recent Events
- 13 Nov 2017 New trial record
 - 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases